C4 Therapeutics begins dosing in Part Ib trial for a number of myeloma
C4 Therapeutics has initiated dosing in a Part Ib examine evaluating cemsidomide and elranatamab (Elrexfio) in sufferers with relapsed or refractory a number of myeloma (r/r MM).
The multicenter, open-label examine goals to find out an optimum dose for cemsidomide when used alongside elranatamab, by assessing preliminary anti-myeloma exercise, tolerability and security.
Uncover B2B advertising that delivers
Mix enterprise intelligence and editorial excellence to succeed in engaged professionals throughout 36 main media platforms.
Extra data
It can enroll roughly 54 sufferers to review cemsidomide, an oral zinc finger protein 1/3 (IKZF1/3) degrader from the ikaros household, together with elranatamab, a B-cell maturation antigen cluster of differentiation 3 (CD3)-targeted bispecific antibody, each with dexamethasone.
The dose ranges being evaluated embrace 50 µg, 75 µg and 100 µg of cemsidomide. The first endpoint focuses on the protection and tolerability of the mixture.
Secondary endpoints will measure anti-myeloma exercise in keeping with response standards established by the Worldwide Myeloma Working Group. This consists of the general response charge, the minimal residual disease-negative full response charge, and the length of response.
C4 Therapeutics expects to report Part Ib information from all cohorts by mid-2027.
Underneath an settlement signed in October 2025, Pfizer will present free elranatamab, whereas C4 Therapeutics will sponsor and handle the examine.
The examine is a part of a broader technique to judge cemsidomide throughout completely different strains of therapy, together with the continued Part II MOMENTUM trial investigating cemsidomide with dexamethasone in fourth-line or later therapies.
C4 Therapeutics additionally plans to judge cemsidomide together with extra anti-myeloma brokers, concentrating on extra complete information and technique updates by mid-2026.
C4 Therapeutics Chief Doctor Len Reyno stated: “Knowledge from our Part I examine helps cemsidomide as a possible best-in-class next-generation IKZF1/3 degrader and the initiation of this Part Ib examine, along with our late-stage Part II MOMENTUM examine, permits an environment friendly path to bringing cemsidomide to the rising populations of myeloma sufferers throughout a number of strains of remedy.
“Bispecific T cell engagers have quickly change into a important therapy mainstay in a number of myeloma, whereas IKZF1/3 degraders stay foundational therapies throughout a number of strains and mixture regimens in a number of myeloma.
“On this mixture with elranatamab, we see a possibility to leverage the highly effective direct anti-myeloma impact of cemsidomide and its potential to strengthen the immune surroundings, which has the potential to supply a deeper and extra sturdy therapeutic response for sufferers, together with these in earlier strains of remedy.”
Final month, C4 Therapeutics administered the primary affected person in its Part II MOMENTUM examine a dose of cemsidomide mixed with dexamethasone for sufferers with r/r MM.
